Effect of Intravesical Botulinum Neurotoxin-A Injection on Detrusor Hyperreflexia in Spinal Cord Injured Patients
Drug Res (Stuttg)DOI: 10.1055/s-0034-1383573 Purpose: To evaluate the effects of Botulinum Toxin A injection into the detrusor muscle on various voiding parameters in spinal cord injured patients with neurogenic detrusor hyperreflexia Materials and methods: 24 patients with spinal cord injuries who had detrusor overactivity and urinary incontinence and were refractory to oral medications, were injected 300 IU of BTX-A into the detrusor muscle. The pre-and post-treatment evaluations included determination of bladder urinary continence status, frequency/volume chart of CIC, Incontinence Quality of Life questionnaire (I-QOL) ...
Source: Drug Research - October 28, 2014 Category: Drugs & Pharmacology Authors: Ge, X.-T.Li, Y.-F.Wang, Q.Zhao, J.-N. Tags: Original Article Source Type: research

Long-term stability of mandibular ramus elongation in severe facial asymmetry
The purpose of this report is to present adjunctive use of botulinum toxin A (Botox) in lengthening the pterygomasseteric sling when correcting hemimandibular hyperplasia. We present the surgical management of a case of severe facial asymmetry with orthognathic surgery using 3-dimensional models in treatment planning and Botox as adjunct therapy. (Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics)
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - October 24, 2014 Category: ENT & OMF Authors: H. Martinez, B. Beltran-Salinas, A. Flores Tags: Oral and maxillofacial surgery Source Type: research

Holmes’ tremor from a lesion of the red nucleus in association with cerebral toxoplasmosis
This report presents the case of a patient who developed a tremor of her right arm, with hemiparesis and ataxia as a result of systemic and cerebral toxoplasmosis in association with AIDS. MRI brain imaging showed a lesion in the contralateral red nucleus in the rostral midbrain, consistent with toxoplasmosis, and confirming the diagnosis of a Holmes’ tremor. The patient responded well, symptomatically, to botulinum toxin (Botox) injections. This case illustrates the importance of neuroimaging in diagnosis of tremor disorders. (Source: Basal Ganglia)
Source: Basal Ganglia - October 17, 2014 Category: Neurology Source Type: research

Factors affecting the health-related quality of life of patients with cervical dystonia and impact of treatment with abobotulinumtoxinA (Dysport): results from a randomised, double-blind, placebo-controlled study
Conclusions CD has a marked impact on HRQOL. Treatment with a single abobotulinumtoxinA injection results in significant improvement in patients’ HRQOL. Trial registration number The trial is registered at ClinicalTrials.gov, numbers NCT00257660 and NCT00288509. (Source: BMJ Open)
Source: BMJ Open - October 16, 2014 Category: Journals (General) Authors: Mordin, M., Masaquel, C., Abbott, C., Copley-Merriman, C. Tags: Open access, Neurology, Qualitative research Source Type: research

False vocal cord botulinum toxin injection for refractory muscle tension dysphonia: Our experience with 7 patients
ConclusionFVC Botox offers benefit to patients with refractory MTD. Best results are obtained with continued voice therapy following injection.This article is protected by copyright. All rights reserved. (Source: Clinical Otolaryngology)
Source: Clinical Otolaryngology - October 14, 2014 Category: ENT & OMF Authors: Paulette C. Pacheco, Selmin Karatayli‐Ozgursoy, Simon Best, Alexander Hillel, Lee Akst Tags: Our Experience Source Type: research

Transurethral Intraprostatic Injection of Botulinum Toxin Type A for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results of a Prospective Pilot Double‐Blind and Randomized Placebo‐Controlled study
Abstract ObjectiveTo evaluate the effect of botulinumneurotoxin type‐A (BoNT‐A) on chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) refractory to medical therapy. Materials and MethodsFrom November 2011 to January 2013, 60 men aged ≥18 years with CP/CPPS, NIH‐CPSI symptom scale score≥10 and pain subscale score≥8, and refractory to 4 to 6 weeks medical therapy underwent transurethral intraprostatic injection of BoNT‐A or normal saline (NS) in a prospective pilot double‐blind randomized study. NIH‐CPSI total and subscale scores, AUA‐SS, VAS and (QoL) scores and frequencies of diurnal and noct...
Source: BJU International - October 13, 2014 Category: Urology & Nephrology Authors: Siavash Falahatkar, Elaheh Shahab, Keivan Gholamjani Moghaddam, Ehsan Kazemnezhad Tags: Upper Urinary Tract Source Type: research

OnabotulinumtoxinA and multiple sclerosis
Publication date: July 2014 Source:Annals of Physical and Rehabilitation Medicine, Volume 57, Issue 5 Author(s): B. Schurch , S. Carda Lower urinary tract dysfunction is present in two of three patients with multiple sclerosis five years after the diagnosis. Most frequent symptoms are related to neurogenic detrusor overactivity, often associated with detrusor-sphincter dyssynergia. From the end of the 1990s, there is growing evidence that neurogenic detrusor overactivity can be effectively managed by intradetrusorial injections of botulinum toxin type A. This treatment has shown, in different randomised placebo-controlle...
Source: Annals of Physical and Rehabilitation Medicine - October 12, 2014 Category: Rehabilitation Source Type: research

Is Hemifacial Spasm a Phenomenon of the Central Nervous System? – The Role of Desflurane on the Lateral Spread Response
Hemi-facial spasm (HFS) is a unilateral, involuntary and irregular twitching of the facial muscles. HFS can be managed clinically using serial botulium toxin (Botox) injections into the affected muscles or surgically treated with microvascular decompression (MVD) of the facial nerve. The etiology of HFS was originally suggested by Gardner (1962) and subsequently refined to include vascular (arterial or venous) compression of the facial nerve at the root entry/exit zone (Janetta et al., 1977; Moller and Jannetta, 1985, 1986, 1987). (Source: Clinical Neurophysiology)
Source: Clinical Neurophysiology - October 11, 2014 Category: Neuroscience Authors: Marshall F. Wilkinson, Tumul Chowdhury, W. Alan C Mutch, Anthony M. Kaufmann Source Type: research

Longitudinal variations of laryngeal overpressure and voice‐related quality of life in spasmodic dysphonia
ConclusionsVariability in self‐ratings of the V‐RQOL suggest that perceived disability related to AdSD should be actively monitored. Further, auditory–perceptual judgments may provide an accurate index of the potential impact of the disorder on the speaker. Similarly, LO was supported as a simple clinical measure that serves as a reliable index of voice change over time. Level of Evidence4. Laryngoscope, 2014 (Source: The Laryngoscope)
Source: The Laryngoscope - October 7, 2014 Category: ENT & OMF Authors: Jeffrey C. Yeung, Kevin Fung, Eric Davis, Sunita K. Rai, Adam M.B. Day, Agnieszka Dzioba, Catherine Bornbaum, Philip C. Doyle Tags: Laryngology Source Type: research

Botulinum toxin type A products are not interchangeable: a review of the evidence
Mitchell F Brin,1,2 Charmaine James,3 John Maltman1 1Allergan, Inc., Irvine, CA, USA; 2Department of Neurology, University of California, Irvine, CA, USA; 3Allergan, Marlow, UKAbstract: Botulinum toxin type A (BoNTA) products are injectable biologic medications derived from Clostridium botulinum bacteria. Several different BoNTA products are marketed in various countries, and they are not interchangeable. Differences between products include manufacturing processes, formulations, and the assay methods used to determine units of biological activity. These differences result in a specific set of interactions between each BoN...
Source: Biologics: Targets and Therapy - October 6, 2014 Category: Biochemistry Tags: Biologics: Targets and Therapy Source Type: research

Radiation-induced Alopecia Treated with Botulinum Toxin Type A Injection
Source: Plastic and Reconstructive Surgery Global Open - October 1, 2014 Category: Cosmetic Surgery Tags: Viewpoints Source Type: research

OnabotulinumtoxinA (Botox) Nerve Blocks Provide Durable Pain Relief for Men with Chronic Scrotal Pain: A Pilot Open‐Label Trial
Abstract IntroductionChronic scrotal pain (CSP) is a common, often debilitating, condition affecting approximately 4.75% of men. While nerve blocks using local anesthetics usually provide temporary pain relief, there are no publications on the use of longer acting nerve blocks to provide more durable pain relief for men with CSP. AimThe aim of this study was to determine if onabotulinumtoxinA (Botox) cord blocks provide durable pain relief for men with CSP. MethodsIn this pilot open‐label study, men with CSP who had failed medical management but experienced temporary pain relief from a standard cord block underwent a cor...
Source: The Journal of Sexual Medicine - October 1, 2014 Category: Sexual Medicine Authors: Aziz Khambati, Susan Lau, Allan Gordon, Keith A. Jarvi Tags: Original Research Source Type: research

Spasticity and Goal Attainment Scale Characteristics in Individuals Receiving Botulinum Toxin Type-A Injections
Goal Attainment Scale (GAS) is used to assess functional gains in response to treatment. Specific characteristics of functional goals set by individuals receiving botulinum toxin type-A (BoNTA) injections for spasticity management are unknown. The primary objective of this study was to describe the characteristics of goals (active vs. passive) set by patients prior to BoNTA injections and determine whether the pattern of spasticity distribution affects the type of goal(s) set. (Source: Archives of Physical Medicine and Rehabilitation)
Source: Archives of Physical Medicine and Rehabilitation - October 1, 2014 Category: Rehabilitation Authors: Jaclyn Peters, Kevin Choi, Elizabeth Chapman, Andrew Tri, Sarah Lim, Farooq Ismail, Chris Boulias, Shannon Gallagher, Chetan P. Phadke Source Type: research

Effect of botulinum toxin type A in lateral abdominal wall muscles thickness and length of patients with midline incisional hernia secondary to open abdomen management
Abstract Purpose Abdominal wall hernia secondary to open abdomen management represents a surgical challenge. The hernia worsens due to lateral muscle retraction. Our objective was to evaluate if Botulinum Toxin Type A (BTA) application in lateral abdominal wall muscles modifies its thickness and length. Methods A clinical trial of male trauma patients with hernia secondary to open abdomen management was performed from January 2009 to July 2011. Thickness and length of lateral abdominal muscles were measured by a basal Computed Tomography and 1 mon...
Source: Hernia - September 28, 2014 Category: Sports Medicine Source Type: research

Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial
Conclusions: BTX-A injection in TN is safe and efficient. It is a useful treatment for refractory TN. Lower dose (25U) and high dose (75U) were similar in efficacy in short-term. (Source: BioMed Central)
Source: BioMed Central - September 27, 2014 Category: Journals (General) Authors: Haifeng ZhangYajun LianYunqing MaYuan ChenCaihong HeNanchang XieChuanjie Wu Source Type: research

Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial
Conclusions BTX-A injection in TN is safe and efficient. It is a useful treatment for refractory TN. Lower dose (25U) and high dose (75U) were similar in efficacy in short-term. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - September 27, 2014 Category: Neurology Source Type: research

Are Nurse Injectors the New Norm?
Abstract Purpose As Botox®/filler use has increased in recent years, a growing number of nonaesthetic health professionals have emerged to perform these procedures. Since studies have shown that patients identify training as the most important factor in considering these procedures, this study seeks to summarize the perspective of plastic surgeons regarding these paradigm shifts. Methods In the summer of 2013, an eight-question survey was sent to members of ISAPS, ASAPS, and ASPS (approximately 26,113 plastic surgeons globally). Two qu...
Source: Aesthetic Plastic Surgery - September 25, 2014 Category: Cosmetic Surgery Source Type: research

Peroral endoscopic myotomy (POEM) leads to similar results in patients with and without prior endoscopic or surgical therapy
Conclusion We found favorable outcomes following POEM in patients who have had prior endoscopic or surgical treatments for achalasia, as well as for patients without prior intervention. There were no significant differences between these two groups with regards to operative times, GERD-HRQL scores, and mental component SF-12 scores. One complication requiring intervention occurred in a patient that had received multiple prior Botox injections and balloon dilatations. POEM appears to be a viable alternative for treatment of achalasia compared to traditional techniques, however, long-term data are needed to establi...
Source: Surgical Endoscopy - September 24, 2014 Category: Surgery Source Type: research

Botulinum toxin type-A injection to treat patients with intractable anismus unresponsive to simple biofeedback training.
CONCLUSION: BTX-A injection combined with pelvic floor biofeedback training seems to be successful for intractable anismus. PMID: 25253964 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - September 21, 2014 Category: Gastroenterology Authors: Zhang Y, Wang ZN, He L, Gao G, Zhai Q, Yin ZT, Zeng XD Tags: World J Gastroenterol Source Type: research

The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders
Abstract Drooling is a common symptom in parkinsonian disorders. Our aim was to assess the safety and effect of botulinum toxin when applied to parotid glands without ultrasound guidance for sialorrhea in parkinsonian disorders in a retrospective study with a long-term follow-up. We evaluated 53 patients (64.2 % male and 35.8 % female) with a mean age of 70.18 ± 9.25 years who were treated in our centre between 2007 and 2013. We analysed the mean dose, latency, effect duration, response and adverse effects of treating sialorrhea by injecting botulinum toxin type A (Botox) into the p...
Source: Neurological Sciences - September 20, 2014 Category: Neurology Source Type: research

EHMTI-0102. Prospective analysis of the use of onabotulinumtoxina (botox ® ) In the treatment of chronic migraine; real-life data in 299 patients from hull, UK
(Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - September 18, 2014 Category: Neurology Source Type: research

Can botulinum toxin type A injection technique influence the clinical outcome of patients with post-stroke upper limb spasticity? A randomized controlled trial comparing manual needle placement and ultrasound-guided injection techniques
Botulinum toxin type A is a first-line treatment for post-stroke focal spasticity, and the accuracy in delivering the toxin to the target muscles may influence the treatment outcome. Our aim was to compare the reduction of spasticity and the related finger position at rest improvement in post-stroke patients treated with botulinum toxin type A in upper limb muscles using ultrasound guidance and manual needle placement. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - September 18, 2014 Category: Neurology Authors: Andrea Santamato, Maria Francesca Micello, Francesco Panza, Francesca Fortunato, Alessio Baricich, Carlo Cisari, Alberto Pilotto, Giancarlo Logroscino, Pietro Fiore, Maurizio Ranieri Source Type: research

Cortical activity modulation by botulinum toxin type A in patients with post-stroke arm spasticity: Real and imagined hand movement
Our aim was to use functional magnetic resonance imaging (fMRI) to compare brain activation changes due to botulinum toxin A (BoNT) application between two chronic stroke patient groups with different degree of weakness treated for upper limb spasticity. (Source: Journal of the Neurological Sciences)
Source: Journal of the Neurological Sciences - September 14, 2014 Category: Neurology Authors: Tomáš Veverka, Petr Hluštík, Pavel Hok, Pavel Otruba, Zbyněk Tüdös, Jana Zapletalová, Alois Krobot, Petr Kaňovský Source Type: research

Use of gait parameters to predict the effectiveness of botulinum toxin injection in the spastic Rectus Femoris muscle of stroke patients with Stiff Knee Gait.
CONCLUSION: The percentage increase in peak knee flexion in swing during fast gait before injection is a useful predictor of the increase in peak knee flexion following RF BTX-A injection in chronic stroke patients with RF spasticity. PMID: 25213306 [PubMed - as supplied by publisher] (Source: European Journal of Physical and Rehabilitation Medicine)
Source: European Journal of Physical and Rehabilitation Medicine - September 12, 2014 Category: Rehabilitation Authors: Roche N, Boudarham J, Hardy A, Bonnyaud C, Bensmail D Tags: Eur J Phys Rehabil Med Source Type: research

The multidisciplinary adult ataxia telangiectasia service
Conclusion In a rare degenerative neurological condition re-evaluation by a specialist MDT, whilst not affecting disease progression, leads to novel interventions to improve patient care. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - September 9, 2014 Category: Neurosurgery Authors: Stavrou, M., Bull, T., Thaivalappil, F., Oscroft, N. Tags: Abstracts Source Type: research

Primary Tracheoesophageal Puncture with Supraclavicular Artery Island Flap after Total Laryngectomy or Laryngopharyngectomy
The supraclavicular artery island flap (SCAIF) is increasingly employed for laryngectomy reconstruction with excellent success. Although tracheoesophageal puncture (TEP) with intraoperative prosthesis placement is also positively reported, this is not described in patients following SCAIF. We review our experience with primary TEP with prosthesis placement and voice outcomes in patients after SCAIF reconstruction. Seven patients underwent SCAIF with primary TEP after laryngectomy from 2011 to 2013. Five underwent total laryngectomy (TL) and 2 underwent TL with partial pharyngectomy. All patients had 16 French Indwelling Bl...
Source: Otolaryngology - Head and Neck Surgery - September 2, 2014 Category: ENT & OMF Authors: Sethi, R. K. V., Kozin, E. D., Lam, A. C., Emerick, K. S., Deschler, D. G. Tags: Facial Plastic and Reconstructive Surgery Source Type: research

Committee Opinion: OnabotulinumtoxinA and the Bladder
AbstractIn January 2013, the US Food and Drug Administration approved the use of onabotulinumtoxinA (also known as Botox A) for the treatment of overactive bladder, thus providing another treatment option for women. Symptoms of overactive bladder have been shown to significantly improve after onabotulinumtoxinA injections compared with no intervention, placebo, pharmacological treatments, and bladder instillation technique. Before considering medical or surgical treatment, all patients in whom overactive bladder is diagnosed should receive instruction in behavioral techniques (eg, bladder retraining drills and timed voids)...
Source: Female Pelvic Medicine and Reconstructive Surgery - September 1, 2014 Category: OBGYN Tags: Committee Opinions Source Type: research

Botox Enhancing Eyebrow Elevation in External Ophthalmoplegia Ptosis
No abstract available (Source: Ophthalmic Plastic and Reconstructive Surgery)
Source: Ophthalmic Plastic and Reconstructive Surgery - September 1, 2014 Category: Opthalmology Tags: Letters to the Editor Source Type: research

A Direct Comparison of OnabotulinumtoxinA (Botox) and IncobotulinumtoxinA (Xeomin) in the Treatment of Benign Essential Blepharospasm: A Split-face Technique
Conclusion:No difference between Xeomin and Botox was detected in either subjective or objective measures for the treatment of BEB. (Source: Journal of Neuro-Ophthalmology)
Source: Journal of Neuro-Ophthalmology - September 1, 2014 Category: Opthalmology Tags: Original Contribution Source Type: research

Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK
Conclusion OnabotulinumtoxinA is a valuable addition to current treatment options in patients with chronic migraine. Our results support findings of PREEMPT study in a large cohort of patients, we believe, is representative of the patients seen in an average tertiary headache centre. While it can be used as a first line prophylaxis its cost may restrict its use to more refractory patients who failed three oral preventive treatments. (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - September 1, 2014 Category: Neurology Source Type: research

Management strategies for achalasia
Abstract Treatment options for achalasia include oral pharmacologic therapy, endoscopic injection of botulinum toxin, pneumatic dilation, and myotomy (conventionally by laparoscopy, but more recently by an endoscopic approach). Oral pharmacologic agents have fallen out of use because of insufficient efficacy and frequent side effects. Endoscopic injection of botulinum toxin is safe and has good short‐term effectiveness, but as the effect invariably wears off after a few months, this treatment is reserved for patients who are not candidates for more definitive treatments. Pneumatic dilation and surgical myotomy are curren...
Source: Neurogastroenterology and Motility - August 28, 2014 Category: Gastroenterology Authors: M. F. Vela Tags: Mini‐Review Source Type: research

Botox blitz could work against stomach cancers
When you think of botox, you are more likely to imagine it smoothing skin than fighting cancer, but the toxin could be effective against stomach tumours (Source: New Scientist - Health)
Source: New Scientist - Health - August 22, 2014 Category: Consumer Health News Source Type: research

Botox blitz could work against stomach cancers
When you think of botox, you are more likely to imagine it smoothing skin than fighting cancer, but the toxin could be effective against stomach tumours (Source: New Scientist - Cancer)
Source: New Scientist - Cancer - August 22, 2014 Category: Cancer & Oncology Source Type: research

Botulinum toxin type a potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: A placebo controlled study
Pisa syndrome (PS) is a tonic lateral flexion of trunk that represents a disabling complication of advanced Parkinson disease (PD).Conventional rehabilitation treatment (CT) ameliorates axial posture and trunk mobility in PD patients, but the improvement tends to wane in 4–6 months. Botulin toxin (BT) may reduce muscle hyperactivity, therefore improving CT effectiveness. We evaluated whether the injection of incabotulinum toxin type A (iBTA) into the hyperactive trunk muscles might improve the effectiveness of rehabilitation in a group of PD patients with PS. (Source: Parkinsonism and Related Disorders)
Source: Parkinsonism and Related Disorders - August 13, 2014 Category: Neurology Authors: C. Tassorelli, R. De Icco, E. Alfonsi, M. Bartolo, M. Serrao, M. Avenali, I. De Paoli, C. Conte, N.G. Pozzi, P. Bramanti, G. Nappi, G. Sandrini Source Type: research

Lipocalin 2: A New Mechanoresponding Gene Regulating Bone Homeostasis
In conclusion, our data indicate that LCN2 is a novel osteoblast mechanoresponding gene and that its regulation could be central to the pathological response of the bone tissue to low mechanical forces. © 2014 American Society for Bone and Mineral Research (Source: Journal of Bone and Mineral Research)
Source: Journal of Bone and Mineral Research - August 12, 2014 Category: Orthopaedics Authors: Nadia Rucci, Mattia Capulli, Sara Gemini Piperni, Alfredo Cappariello, Patrick Lau, Petra Frings‐Meuthen, Martina Heer, Anna Teti Tags: Original Article Source Type: research

Establishment of alternative potency test for botulinum toxin type A using compound muscle action potential (CMAP) in rats.
In this study, to evaluate this quantitative method of measuring toxin activity using CMAP, we assessed the parameters necessary for quantitative tests according to ICH Q2 (R1). This assay could be used to evaluate the activity of the toxin, even when inactive toxin was mixed with the sample. To reduce the number of animals needed, this assay was set to measure two samples per animal. Linearity was detected over a range of 0.1∼12.8 U/mL, and the measurement range was set at 0.4∼6.4 U/mL. The results for accuracy and precision showed low variability. The body weight was selected as a variable factor, but it showed n...
Source: Toxicon - August 7, 2014 Category: Toxicology Authors: Torii Y, Goto Y, Nakahira S, Ginnaga A Tags: Toxicon Source Type: research

Effectiveness of botulinum toxin treatment and rehabilitation program in lateral axial dystonia in Parkinson's disease
Introduction: The trunk dystonia in idiopathic Parkinson's disease characterized by marked flexion of the thoraco-lumbar spine, associated or not with rotation of the spine along the sagittal plane, is often referred to as Pisa syndrome (PS). Pisa syndrome is synonymous of a lateral axial dystonia (LAD) [1]. The principal aim of this study was to evaluate with clinical, radiological and gait analysis patterns the effect of botulinum toxin type A (BTX-A) injection and a specific rehabilitation on LAD in patients affected by Parkinson's disease. (Source: Gait and Posture)
Source: Gait and Posture - August 1, 2014 Category: Orthopaedics Authors: M. Bacchini, G. Chiari, C. Lapiana, M. Rossi Source Type: research

[Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrom.]
CONCLUSION: Botulinum toxin detrusor injections may be offered to women who develop refractory OAB. PMID: 25087018 [PubMed - as supplied by publisher] (Source: Reproductive Biology)
Source: Reproductive Biology - July 30, 2014 Category: Reproduction Medicine Authors: Deffieux X, Fatton B, Denys P, Chartier-Kastler E, Amarenco G, Haab F, Costa P, Game X, Karsenty G, Saussine C, Ballanger P, Le Normand L, Ruffion A, Hermieu JF, Cosson M Tags: J Gynecol Obstet Biol Reprod (Paris) Source Type: research

Takeover battle pushes Allergan to cut R&D jobs
Besieged by serially acquisitive Valeant, the Botox maker will lay off 1500 staff to propel earnings growth (Source: Chemistry World | Latest News)
Source: Chemistry World | Latest News - July 28, 2014 Category: Chemistry Authors: Andy Extance Source Type: research

Architectural changes of the gastrocnemius muscle after botulinum toxin type a injection in children with cerebral palsy.
This study used ultrasonography (US) to investigate the architectural changes in gastrocnemius muscles (GCM) after botulinum toxin injection (BoNT-A) in children with cerebral palsy (CP). MATERIALS AND METHODS: Thirteen children with CP who received a BoNT-A injection into their GCM to treat equinus were recruited (9 males and 4 females). Architectural changes in both the medial and lateral heads of the GCM from a total of 20 legs were assessed using B-mode, real-time US. Muscle thickness (MT), fascicle length (FL), and fascicle angle (FA) were measured over the middle of the muscle belly in both a resting and neutral...
Source: Yonsei Medical Journal - July 25, 2014 Category: Universities & Medical Training Authors: Park ES, Sim E, Rha DW, Jung S Tags: Yonsei Med J Source Type: research

Heart rate variability (hrv) modifications in adult hemiplegic patients after botulinum toxin type a (nt-201) injection.
CONCLUSION: The use of incobotulinumtoxinA in adult patients at doses up to 12 units/kg seems to be safe regarding autonomic heart drive. CLINICAL REHABILITATION IMPACT: The use of IncobotulinumtoxinA up to 600 units could be a safe therapeutic option in spastic hemiplegic stroke survivors. PMID: 25051207 [PubMed - as supplied by publisher] (Source: European Journal of Physical and Rehabilitation Medicine)
Source: European Journal of Physical and Rehabilitation Medicine - July 22, 2014 Category: Rehabilitation Authors: Invernizzi M, Carda S, Molinari C, Stagno D, Cisari C, Baricich A Tags: Eur J Phys Rehabil Med Source Type: research

Bilateral gustatory sweating in the submandibular region after bilateral neck dissection successfully treated with botulinum toxin
We report a 66-year-old patient who had been referred for the management of a squamous cell carcinoma of the mobile tongue. She was treated by bilateral neck dissection and bilateral resection of the submandibular glands. Bilateral gustatory sweating in the submandibular region developed 10 years later and was successfully treated with bilateral injections of botulinum toxin type A. (Source: The British Journal of Oral and Maxillofacial Surgery)
Source: The British Journal of Oral and Maxillofacial Surgery - July 3, 2014 Category: ENT & OMF Authors: Pierre Philouze, Delphine Vertu, Philippe Ceruse Tags: Short Communications Source Type: research

Frey’s Syndrome Prevention, Treatment Following Parotid Surgery
Parotid parenchyma-sparing procedures, interpositional grafts aid in prevention; intradermal botulinum toxin type A injections may be used in treatment (Source: ENTtoday - TRIO Best Practices)
Source: ENTtoday - TRIO Best Practices - July 2, 2014 Category: ENT & OMF Authors: Robert L. Witt, MD, and Edmund A. Pribitkin, MD Tags: Head and Neck Practice Focus TRIO Best Practices parotid surgery Source Type: research

Treatment of interstitial cystitis/painful bladder syndrome as a neuropathic pain condition
Lakshmi Vas, Manorama Pattanik, Vaishali TitarmoreIndian Journal of Urology 2014 30(3):350-353A lady of 52 years with painful bladder syndrome/interstitial cystitis (PBS/IC) presented with chronic pelvic pain, irritative voiding with sphincter dominance on urodynamics. 3 yrs of oral analgesics, antispasmodics and intravesical therapy was ineffective. We surmised her pain, and irritative voiding to be secondary to constant straining against a dysfunctional pelvic floor. We treated PBS/IC as a neuropathic phenomenon with a combination of neuromodulator medications and continuous caudal epidural analgesia to reduce the pain i...
Source: Indian Journal of Urology - July 1, 2014 Category: Urology & Nephrology Authors: Lakshmi VasManorama PattanikVaishali Titarmore Source Type: research

Change of distribution and timing of bite force after botulinum toxin type a injection evaluated by a computerized occlusion analysis system.
CONCLUSION: A decline in the difference in the clenching force between the left and right sides was found with increasing time up to 12 weeks following BTX-A injection. PMID: 24954346 [PubMed - in process] (Source: Yonsei Medical Journal)
Source: Yonsei Medical Journal - June 29, 2014 Category: Universities & Medical Training Authors: Song JH, Cho ES, Kim ST, Ahn HJ Tags: Yonsei Med J Source Type: research

Merz buying Mesa medical device company Ulthera for $600M
Merz, the German pharmaceutical company Merz that has its U.S.headquarters in North Carolina, has agreed to buy Arizona medical device company Ulthera for $600 million in upfront cash and milestone payments. That would be the largest deal yet for the fast-growing Merz, which makes products for the aesthetics, dermatology and neurosciences markets. Among its products are dermal fillers Radiesse and Belotero and Xeomin, a competitor to Botox. Ulthera is also in the aesthetics niche, but as a medical… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 26, 2014 Category: Pharmaceuticals Authors: Matt Evans Source Type: research

Merz buying Mesa medical device company Ulthera for $600M
Merz, the German pharmaceutical company Merz that has its U.S.headquarters in North Carolina, has agreed to buy Arizona medical device company Ulthera for $600 million in upfront cash and milestone payments. That would be the largest deal yet for the fast-growing Merz, which makes products for the aesthetics, dermatology and neurosciences markets. Among its products are dermal fillers Radiesse and Belotero and Xeomin, a competitor to Botox. Ulthera is also in the aesthetics niche, but as a medical… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 26, 2014 Category: Biotechnology Authors: Matt Evans Source Type: research

Merz buying medical device company Ulthera for $600M
Merz, the German pharmaceutical company Merz that has its U.S.headquarters in High Point, has agreed to buy Arizona medical device company Ulthera for $600 million in upfront cash and milestone payments. That would be the largest deal yet for the fast-growing Merz, which makes products for the aesthetics, dermatology and neurosciences markets. Among its products are dermal fillers Radiesse and Belotero and Xeomin, a competitor to Botox. Ulthera is also in the aesthetics niche, but as a medical… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 26, 2014 Category: Pharmaceuticals Authors: Matt Evans Source Type: research

Merz buying medical device company Ulthera for $600M
Merz, the German pharmaceutical company Merz that has its U.S.headquarters in High Point, has agreed to buy Arizona medical device company Ulthera for $600 million in upfront cash and milestone payments. That would be the largest deal yet for the fast-growing Merz, which makes products for the aesthetics, dermatology and neurosciences markets. Among its products are dermal fillers Radiesse and Belotero and Xeomin, a competitor to Botox. Ulthera is also in the aesthetics niche, but as a medical… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 26, 2014 Category: Biotechnology Authors: Matt Evans Source Type: research